Session Information
Date: Wednesday, June 7, 2017
Session Title: Spasticity
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To evaluate the effectiveness of incobotulinumtoxinA for treating key clinical patterns of lower limb (LL) spasticity (eg, pes equinovarus) using a post-hoc analysis.
Background: IncobotulinumtoxinA has been shown to be safe and effective for the treatment of upper limb (UL) spasticity.
Methods: The TOWER study (NCT01603459) evaluated escalating fixed total doses of incobotulinumtoxinA (400, 600 and 600-800U, respectively) for the treatment of UL and LL spasticity in 155 adult subjects (18-80 years). Muscle tone was assessed using the Ashworth Scale (AS); additional outcome measures included AS responder rates (defined as patients with ≥1 point improvement at 4-weeks) and Resistance to Passive Movement Scale (REPAS).
Results: 109 subjects received LL treatment for any clinical pattern in cycle 1, and the most frequently treated pattern was pes equinovarus (N=100). Nine total LL clinical patterns were treated during the study. For the pes equinovarus pattern, the mean ± standard deviation [SD] dose was 166.3±94.9 U during the first cycle. At 4-weeks, the mean improvement (± SD) in ankle joint AS score was ‑0.63±0.76 in subjects treated for pes equinovarus, compared with ‑0.16±0.63 among subjects not treated for this pattern. Multiple regression analysis (adjusting for AS baseline value) revealed a significant effect of pes equinovarus dose on AS improvement (P=0.0096). AS responder rates were significantly higher among treated subjects compared with those who were untreated (55.0% vs 12.7%; P<0.0001). Four weeks after injection, the mean (± SD) REPAS LL score improvement from baseline was ‑1.6 ± 2.0 in subjects with LL treatment, compared with ‑0.3 ± 1.5 in subjects without. Multiple regression analysis on LL REPAS baseline value and LL dose revealed a significant dose effect (P=0.0022).
Conclusions: Results from this post-hoc analysis demonstrate that incobotulinumtoxinA is safe and effective for the treatment of LL spasticity.
To cite this abstract in AMA style:
D. Simpson, J. Wissel, D. Bensmail, A. Scheschonka, B. Flatau-Baqué, O. Simon. Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/efficacy-of-incobotulinumtoxina-in-treatment-of-lower-limb-spasticity-in-adults/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/efficacy-of-incobotulinumtoxina-in-treatment-of-lower-limb-spasticity-in-adults/